Sign In
Buy RARE
$22.41
+0.630 (+2.89%)
At Close: Jun 03, 2026
Ultragenyx Pharmaceuticals Analyst Turns Bullish: What Investors Need To Know
03:31pm, Tuesday, 29'th Jun 2021
A BofA Securities analyst is turning bullish on shares of Ultragenyx Pharmaceuticals (NASDAQ:RARE). Here's why.
Alzheimer's Approval Validates Biopharmaceutical Innovation
06:49am, Sunday, 20'th Jun 2021
FDA approval of Biogen's Aduhelm for Alzheimer's should be broadly supportive of biotechnology and pharmaceutical stocks as it signals the agency is willing to be flexible to make important drugs. The
New Strong Sell Stocks for June 18th
12:02pm, Friday, 18'th Jun 2021
OEG, EAF, RARE, EGRX, and TELA have been added to the Zacks Rank #5 (Strong Sell) List on June 18, 2021
Patient enrollment to begin in early second half of 2021 in U.K. and Canada
Ultragenyx to Present at Goldman Sachs 42nd Annual Healthcare Conference
04:01pm, Thursday, 03'rd Jun 2021
NOVATO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser
Ultragenyx to Present at Jefferies Virtual Healthcare Conference
08:31am, Wednesday, 26'th May 2021
NOVATO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for seri
GeneTx Bio-Ultragenyx's Angelman Syndrome Study To Start Enrollment In Canada
03:23pm, Wednesday, 19'th May 2021
GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) have received clearance from Health Canada to begin enrolling in the Phase 1/2 study of GTX-102 pediatric patients with
SARASOTA, Fla. and NOVATO, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of intrathecall
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 18'th May 2021
NOVATO, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare
Ultragenyx's Gene Therapies For Genetic Metabolic Disorders Show Longer-Term Durable Responses
02:33pm, Friday, 14'th May 2021
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) has announced longer-term data from the Glycogen Storage Disease Type Ia (GSDIa) and Ornithine Transcarbamylase (OTC) Deficiency Phase 1/2 studies. Dat
Durable and Clinically Meaningful Responses Maintained at More than 2.5 and 3 Years Post-Treatment in Phase 1/2 Studies of DTX401 for GSDIa and DTX301 for OTC
Ultragenyx to Present at Bank of America Securities Healthcare Conference
04:01pm, Monday, 10'th May 2021
NOVATO, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for seri
TOKYO--(BUSINESS WIRE)--Self-administration of CRYSVITA could help healthcare professionals meet the needs of XLH patients during and beyond the COVID-19 pandemic
Ultragenyx (RARE) Q1 Loss Narrows Y/Y, Revenues Beat Estimates
08:39am, Wednesday, 05'th May 2021
Ultragenyx Pharmaceutical (RARE) Q1 sales increase year over year while loss narrows
Ultragenyx Pharmaceutical Inc.'s (RARE) CEO Emil Kakkis on Q1 2021 Results - Earnings Call Transcript
01:54am, Wednesday, 05'th May 2021
Ultragenyx Pharmaceutical Inc.'s (RARE) CEO Emil Kakkis on Q1 2021 Results - Earnings Call Transcript
